BridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the ...

Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...

Explore the exciting world of BridgeBio Pharma (NASDAQ: BBIO) with our expert analysts in this Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...

BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...

BridgeBio Oncology Therapeutics, which was spun out of BridgeBio Pharma (NASDAQ:BBIO) last year, has agreed to merge with ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...

In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...

BofA raised the firm’s price target on BridgeBio (BBIO) to $46 from $45 and keeps a Buy rating on the shares after accounting for the updated ...

BridgeBio's launch of Attruby in the U.S. is off to a strong start. Read how this successful effort puts the biotech in a ...

BridgeBio Oncology Therapeutics, a company working to advance the field of therapies addressing a validated but elusive group of cancer targets, has reached a deal to go public in a SPAC merger ...